NEW YORK ─ Cleveland-based Canary Health Technologies and Delhi-based Divoc Laboratories on Sunday announced that they will collaborate in a clinical trial to develop a rapid breath test for the detection of COVID-19.
The handheld test, called ASU Detect CV19, uses exhaled volatile organic compounds (VOCs) in human breath as biomarkers of the coronavirus that causes COVID-19.